by Tobias F. Marton, MD, PhD | Oct 12, 2021 | Uncategorized
Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression Presented on Tuesday 12th October 2021 | 5.30 PM (BST UK time) | 12:30 PM (EDT NY time) | 9.30 AM (PDT LA time) Steven Pennybaker, Brian J Roach,...
by Megha Vasavada, PhD | Sep 28, 2021 | Uncategorized
Effects of Serial Ketamine Infusions on Corticolimbic Functional Connectivity in Major Depression Presented on Tuesday 28th September 2021 | 12.30pm EDT NY Time | 9:30am PDT LA Time| 5.30pm BST UK Time Megha M Vasavada, Joana Loureiro, Antoni Kubicki, Ashish Sahib,...
by Bardia Nourbakhsh, MD | Sep 14, 2021 | Uncategorized
Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue Presented on Tuesday 14th September 2021 | 12.30pm EDT | 5.30pm UK Kathryn C Fitzgerald, Bridget Morris, Aurash Soroosh, Alexandra Balshi,...
by Jolien K.E. Veraart, MD | Jul 27, 2021 | Uncategorized
Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review Presented on Tuesday 27th July 2021 | 12.30pm EDT | 5.30pm UK Jolien Veraart, Sanne Smith-Apeldoorn, Iris Bakker, Berber Visser, Jeanine...
by Elias Dakwar, MD | Jul 13, 2021 | Uncategorized
Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial Presented on Tuesday 13th July 2021 12.30pm EST; 5.30pm UK Rebecca L Rothberg, Nour Azhari, Nancy A Haug, Elias Dakwar. J...
by Patrick Morris, PhD | Jun 22, 2021 | Uncategorized
A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801 Presented on Tuesday 22nd June 2021 12.30pm EST; 5.30pm UK Patrick J Morris, Richard D Burke, Alok K Sharma, Daniel C Lynch, Leslie E...
